🇺🇸 FDA
Patent

US 11234994

Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

granted A61KA61K31/7105A61K31/713

Quick answer

US patent 11234994 (Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof) held by Benitec Biopharma Limited expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Benitec Biopharma Limited
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/7105, A61K31/713, A61K48/005, A61P